Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.
Southwest Research Institute (SwRI) has developed new technology to enhance clinical bone imaging and decrease osteoporotic ...
Romosozumab plus alendronate led to a greater improvement in bone strength than alendronate alone in postmenopausal women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback